Page 2 - Actinium News Today

Actinium (ACM) traded 0.6% higher against the dollar during the 24 hour period ending at 18:00 PM E.T. on April 1st. One Actinium coin can now be purchased for $0.0153 or 0.00000033 BTC on cryptocurrency exchanges. Actinium has a market capitalization of $616,037.82 and $8,762.00 worth of Actinium was traded on exchanges in the last […]

Actinium (ACM) traded 0.9% lower against the dollar during the 1-day period ending at 19:00 PM Eastern on March 30th. Over the last week, Actinium has traded 8.9% lower against the dollar. Actinium has a total market capitalization of $640,951.75 and approximately $13,154.00 worth of Actinium was traded on exchanges in the last day. One […]

WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) reported data from the phase 1 portion of its Actimab-A and venetoclax combination trial in patients with relapsed or refractory acute

WASHINGTON (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) reported updated data from the recently complete Actimab-A and CLAG-M phase 1 combination trial for patients with relapsed or refractory

Helping to expedite the commercialization of a type of radiation therapy that is effective against cancer which has spread widely through bodyTOKYO, Oct 19, 2021 - (JCN Newswire) - Hitachi, Ltd. (TSE:

Actinium Pharma Announces Research Collaboration With Astellas TOKYO (dpa-AFX) - Actinium Pharmaceuticals, Inc. (ATNM) announced the research collaboration with Astellas Pharma Inc. (ALPMY, ALPMY) to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform. Actinium will utilize its AWE Platform technology to develop and characterize selected Astellas targeting agents labeled with the potent alpha-emitting radioisotope Actinium-225. Actiniums AWE technology paten...